Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Development of potent antagonists for formyl peptide receptor 1 based on Boc-Phe-D-Leu-Phe-D-Leu-Phe-OH.

Hayashi R, Kitajima T, Mizuguchi H, Fujimoto M, Yamaguchi A, Koga S, Koga Y, Osada S, Kodama H.

Bioorg Med Chem. 2014 Aug 1;22(15):3824-8. doi: 10.1016/j.bmc.2014.06.048. Epub 2014 Jul 8.

PMID:
25035262
2.

Cyclosporin H, Boc-MLF and Boc-FLFLF are antagonists that preferentially inhibit activity triggered through the formyl peptide receptor.

Stenfeldt AL, Karlsson J, Wennerås C, Bylund J, Fu H, Dahlgren C.

Inflammation. 2007 Dec;30(6):224-9. Epub 2007 Aug 9.

PMID:
17687636
3.

The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1.

Stenfeldt AL, Karlsson J, Wennerås C, Bylund J, Fu H, Dahlgren C.

Biochem Pharmacol. 2007 Oct 1;74(7):1050-6. Epub 2007 Jul 7.

PMID:
17692291
4.
5.

C- and N-terminal residue effect on peptide derivatives' antagonism toward the formyl-peptide receptor.

Dalpiaz A, Ferretti ME, Vertuani G, Traniello S, Scatturin A, Spisani S.

Eur J Pharmacol. 2002 Feb 2;436(3):187-96.

PMID:
11858798
6.

The synthetic chemoattractant Trp-Lys-Tyr-Met-Val-DMet activates neutrophils preferentially through the lipoxin A(4) receptor.

Dahlgren C, Christophe T, Boulay F, Madianos PN, Rabiet MJ, Karlsson A.

Blood. 2000 Mar 1;95(5):1810-8.

7.

Cathepsin G-regulated release of formyl peptide receptor agonists modulate neutrophil effector functions.

Woloszynek JC, Hu Y, Pham CT.

J Biol Chem. 2012 Oct 5;287(41):34101-9. doi: 10.1074/jbc.M112.394452. Epub 2012 Aug 9.

8.

The immunosuppressant cyclosporin A antagonizes human formyl peptide receptor through inhibition of cognate ligand binding.

Yan P, Nanamori M, Sun M, Zhou C, Cheng N, Li N, Zheng W, Xiao L, Xie X, Ye RD, Wang MW.

J Immunol. 2006 Nov 15;177(10):7050-8.

9.

Selective inhibition of N-formylpeptide-induced neutrophil activation by carbamate-modified peptide analogues.

Derian CK, Solomon HF, Higgins JD 3rd, Beblavy MJ, Santulli RJ, Bridger GJ, Pike MC, Kroon DJ, Fischman AJ.

Biochemistry. 1996 Jan 30;35(4):1265-9.

PMID:
8573582
11.
12.

The rabbit neutrophil N-formyl peptide receptor. cDNA cloning, expression, and structure/function implications.

Ye RD, Quehenberger O, Thomas KM, Navarro J, Cavanagh SL, Prossnitz ER, Cochrane CG.

J Immunol. 1993 Feb 15;150(4):1383-94.

PMID:
8432984
13.

The annexin I sequence gln(9)-ala(10)-trp(11)-phe(12) is a core structure for interaction with the formyl peptide receptor 1.

Movitz C, Brive L, Hellstrand K, Rabiet MJ, Dahlgren C.

J Biol Chem. 2010 May 7;285(19):14338-45. doi: 10.1074/jbc.M109.080465. Epub 2010 Mar 10.

14.
15.

High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists.

Schepetkin IA, Kirpotina LN, Khlebnikov AI, Quinn MT.

Mol Pharmacol. 2007 Apr;71(4):1061-74. Epub 2007 Jan 17.

18.

Mycobacteria attenuate nociceptive responses by formyl peptide receptor triggered opioid peptide release from neutrophils.

Rittner HL, Hackel D, Voigt P, Mousa S, Stolz A, Labuz D, Schäfer M, Schaefer M, Stein C, Brack A.

PLoS Pathog. 2009 Apr;5(4):e1000362. doi: 10.1371/journal.ppat.1000362. Epub 2009 Apr 3.

19.

F2L, a peptide derived from heme-binding protein, inhibits formyl peptide receptor-mediated signaling.

Lee HY, Lee SY, Shin EH, Kim SD, Kim JM, Lee MS, Ryu SH, Bae YS.

Biochem Biophys Res Commun. 2007 Aug 10;359(4):985-90. Epub 2007 Jun 8.

PMID:
17577578
20.

An urokinase receptor antagonist that inhibits cell migration by blocking the formyl peptide receptor.

Bifulco K, Longanesi-Cattani I, Gargiulo L, Maglio O, Cataldi M, De Rosa M, Stoppelli MP, Pavone V, Carriero MV.

FEBS Lett. 2008 Apr 2;582(7):1141-6. doi: 10.1016/j.febslet.2008.03.001. Epub 2008 Mar 11.

Items per page

Supplemental Content

Write to the Help Desk